Ista Pharmaceuticals (NASDAQ:ISTA) shares increased 7.8% after the company was acquired for $500 million in cash by Bausch + Lomb.ISTA Pharmaceuticals (NASDAQ:ISTA) has potential upside of 16.3% based on a current price of $9.03 and an average consensus analyst price target of $10.5.ISTA Pharmaceuticals is currently above its 50-day moving average (MA) of $8.25 and above its 200-day of $6.00.In the last five trading sessions, the 50-day MA has climbed 0.74% while the 200-day MA has remained constant.
